오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - honey, quantity: 150 mg/ml - oral liquid - excipient ingredients: glycerol; purified water; sucrose; sodium benzoate; liquid glucose; citric acid; flavour - decrease/reduce/relieve the severity of common cold symptoms (linked indication:relieve dry unproductive cough); relieve dry unproductive cough ; relieve symptoms of sore throat/pharyngitis (linked indication:relieve dry unproductive cough)

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

nova pharmaceuticals australasia pty ltd - honey, quantity: 150 mg/ml - oral liquid - excipient ingredients: glycerol; purified water; sucrose; sodium benzoate; liquid glucose; citric acid; flavour - decrease/reduce/relieve the severity of common cold symptoms (linked indication:relieve dry unproductive cough); relieve dry unproductive cough ; relieve symptoms of sore throat/pharyngitis (linked indication:relieve dry unproductive cough)

케냐 - 영어 - Pharmacy and Poisons Board

raptakos, brett & co. ltd. raptakos, brett & co. ltd, dr. annie besant road, - honey, navasagar, dashmool, terminalia belerica,… - syrup - each 5ml contains: honey 1.25g, navasagar 15mg,… - cough and cold preparations

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

nod apiary ireland limited - formic acid - bee-hive strip - 68.2 gram(s)/strip - formic acid

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

melcare biomedical pty ltd - 47773 - medical-honey liquid barrier dressing, non-sterile - oral therapeutic products are high viscosity liquids formed from medical grade honeys intended to provide a transient non-occlusive coating to the mouth and throat when taken orally. they provide relief to the symptoms of upper respiratory tract infections, namely cough and sore throat. they also help to maintain a moist environment this is a single-use device

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

nod apiary ireland limited - formic acid - bee-hive strip - 68.2 gram(s)/strip - formic acid

미국 - 영어 - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar thin honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. varibar thin honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar thin honey risk summary varibar thin honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar thin honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar thin honey in pediatric patients is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients are based on clinical experience. varibar thin honey is contraindicated in pediatric patients with trachea-esophageal fistula. [see contraindications (4)]. pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5.1)]. monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar thin honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

미국 - 영어 - NLM (National Library of Medicine)

e-z-em canada inc - barium sulfate (unii: 25bb7eke2e) (barium sulfate - unii:25bb7eke2e) - barium sulfate 400 mg in 1 ml - varibar honey is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients 6 months of age and older. varibar honey is contraindicated in patients with: - known or suspected perforation of the gastrointestinal (gi) tract - known obstruction of the gi tract - high risk of gi perforation such as those with a recent gi perforation, acute gi hemorrhage or ischemia, toxic megacolon, severe ileus, post gi surgery or biopsy, acute gi injury or burn, or recent radiotherapy to the pelvis - high risk of aspiration such as those with known or suspected tracheo-esophageal fistula or obtundation - known severe hypersensitivity to barium sulfate or any of the excipients of varibar honey risk summary varibar honey is not absorbed systemically following oral administration, and maternal use is not expected to result in fetal exposure to the drug. risk summary varibar honey is not absorbed systemically by the mother following oral administration, and breastfeeding is not expected to result in exposure of the infant to the drug. the efficacy of varibar honey in pediatric patients above 6 months of age is based on successful opacification of the pharynx during modified barium swallow examinations [see clinical pharmacology (12.1)] . safety and dosing recommendations in pediatric patients above 6 months of age are based on clinical experience. varibar honey is contraindicated in pediatric patients with trachea-esophageal fistula [see contraindications (4)] . pediatric patients with a history of asthma or food allergies may be at increased risk for development of hypersensitivity reactions [see warnings and precautions (5. 1)] . monitor patients with cystic fibrosis or hirschsprung disease for bowel obstruction after use [see warnings and precautions (5.3)] . clinical studies of varibar honey did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - dextromethorphan hydrobromide monohydrate, quantity: 10.5 mg - pastille - excipient ingredients: menthol; acacia; saccharin sodium; white beeswax; betadex; quinoline yellow; sodium cyclamate; light liquid paraffin; maltitol solution; citric acid; flavour - bisolvon dry pastilles are used for the symptomatic treatment of dry, irritant, unproductive coughs and helps soothe the throat.

이스라엘 - 영어 - Ministry of Health

cts chemical industries ltd, israel - carbocisteine - lozenges - carbocisteine 375 mg - carbocisteine - carbocisteine - treatment of disorders of the respiratory tract characterised by excessive or viscous mucus.